Welcome to our dedicated page for Lifeloc Technologies news (Ticker: LCTC), a resource for investors and traders seeking the latest updates and insights on Lifeloc Technologies stock.
Lifeloc Technologies, Inc. (LCTC) generates a steady stream of news around its work in breath alcohol testing and drug-of-abuse detection. As a U.S.-based manufacturer of evidential breath alcohol testers and related training and supplies for workplace, law enforcement, corrections and international customers, the company regularly issues updates on financial performance, product development and corporate transactions.
News coverage for Lifeloc often includes quarterly and annual results, where the company discusses revenue trends, gross margins and the impact of research and development spending, particularly related to its SpinDetect/SpinDx centrifugal drug analyzer platform. These releases explain how investment in microfluidic “lab-on-a-disk” technology affects operating results and outline the company’s priorities in advancing rapid, on-site drug testing.
Another major theme in Lifeloc’s news is product innovation. The company has announced live demonstrations and beta testing of its SpinDetect/SpinDx oral-fluid drug analyzer, including reports of laboratory validation against LCMS methods and the ability to detect substances such as delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA and benzodiazepines. News items also highlight enhancements to L-series LX9 and LT7 breath alcohol devices, such as smart phone pairing, wider temperature ranges and localization features.
Lifeloc’s press releases additionally cover financing and strategic developments, including subordinated debenture financings, private placements, a line of credit, and an Agreement and Plan of Merger with Electronic Systems Technology, Inc. Investors and observers who follow LCTC news can track how these events relate to the company’s efforts to commercialize SpinDetect/SpinDx and support its installed base of breath alcohol testing equipment. For ongoing insight into Lifeloc’s operations, product roadmap and capital strategy, this news feed provides a consolidated view of its publicly released information.
Lifeloc Technologies (OTC:LCTC) reported Q3 2025 results for the quarter ended Sept 30, 2025: Q3 net revenue $2.257M and a quarterly net loss $263k (EPS $(0.10)), versus Q3 2024 revenue $2.087M and loss $158k. Nine‑month 2025 net revenue was $6.754M with a YTD net loss $950k (EPS $(0.35)). Gross margin declined to 40.2% in Q3 (43.7% year‑ago) due to inflation and tariffs. Management cited high R&D spending to commercialize the SpinDetect™ centrifugal drug‑analyzer.
Operational highlights: lab validation of SpinDetect versus LCMS at ~10 ng/ml detection limits, signed beta‑testing agreement for an oral‑fluid THC analyzer, prototype demonstrations at trade shows, and a Form S‑4 filed Oct 15, 2025 for the proposed acquisition of Electronic Systems Technology (ELST).
Lifeloc Technologies (OTC:LCTC), a manufacturer of breath alcohol and drug detection devices, will present at the Emerging Growth Conference on September 25, 2025, at 2:20 PM EDT. CEO Dr. Wayne Willkomm will provide an operational overview and update on the SpinDetect™ centrifugal drug analyzer, the company's next-generation drug screening platform under development.
The interactive virtual presentation will include a Q&A session, with questions accepted both in advance and during the event. A recording will be available post-event on the Emerging Growth website and YouTube channel.
Lifeloc Technologies (OTCID:LCTC) has unveiled its innovative SpinDetect™ Centrifugal Drug Analyzer at the International Association of Chiefs of Police Conference in Chicago. The system processes oral fluid samples in under 15 minutes, delivering lab-grade analytical chemistry on a compact, automated disk platform.
The analyzer, based on licensed SpinDx™ microfluidic technology from Sandia Corporation, can detect multiple substances including delta-9-THC at 10 ng/ml, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines. The company plans a phased commercial launch starting in 2026, initially focusing on THC detection disks, followed by expanded drug panels and additional sample types from blood and breath.
Lifeloc Technologies (OTCID:LCTC), a breath alcohol and drug testing device manufacturer, reported Q2 2025 financial results with net revenue of $2.219 million, down 7% year-over-year, and a net loss of $(394) thousand or $(0.14) per share.
The company maintained a gross margin of 41.7% while investing heavily in R&D ($623 thousand) for SpinDx development. Their strategic focus remains on the SpinDx technology platform for rapid drug detection, with commercial launch projected for early 2026. The platform has demonstrated effectiveness in detecting multiple drugs including THC, cocaine, and fentanyl.
Lifeloc has been approved for trading on the OTCID market tier, upgrading from OTC Pink Current Market as of July 1, 2025.
Lifeloc Technologies (OTC PINK:LCTC) reported its 2024 fiscal year results, showing an 8% revenue decline to $8.538 million from $9.330 million in 2023. The company posted a net loss of ($1.053) million, or ($0.41) per diluted share, compared to a net profit of $205.6 thousand in 2023. Gross margin decreased to 40.4% from 43.3%.
The decline was attributed to normalized demand following 2023's pent-up demand and inflation's impact on customer budgets. The company's L-series devices (LX9 and LT7) are gaining market penetration with features like smartphone pairing and local language customization.
Lifeloc is heavily investing in SpinDx technology development, a 'Lab on a Disk' platform for rapid drug detection. Beta testing of the SpinDx saliva testing system for THC detection is planned for Q2 2025, with commercial launch projected for early 2026. To support development, the company secured a $750,000 debenture in late 2024 and an additional $75,000 in Q1 2025.
Lifeloc Technologies (OTC PINK:LCTC) has secured a $750,000 financing through a subordinated debenture agreement with Diamond Bridge Capital, LP. The deal includes a warrant to purchase 62,500 shares at $4.50 per share and carries an 8.25% annual interest rate, maturing December 31, 2030.
The funding will support growth initiatives and R&D efforts, particularly the commercialization of SpinDx technology, which aims to revolutionize drug testing by providing quick, local results within minutes at approximately $25 per test, compared to current lab testing costs of $100-$300 with longer wait times.
The company plans to launch SpinDx in Q4 2025, with ongoing efforts to reduce the prototype reader size by 25%. Lifeloc has confirmed the technology's accuracy through in-house testing with samples from Anschutz Medical Center and plans to establish beta test sites for further validation.
Lifeloc Technologies (LCTC) reported Q3 2024 financial results with net revenue of $2.087 million, down 23% from $2.696 million in Q3 2023. The company posted a quarterly net loss of $(158) thousand, or $(0.06) per share, compared to a profit of $110 thousand, or $0.04 per share in Q3 2023. Gross margin improved to 43.7% from 41.5% year-over-year. The company secured a $750,000 line of credit and raised $798,000 through a private placement of 210,000 shares at $3.80 per share. Lifeloc plans to launch its SpinDx saliva testing system for drug detection in late 2025.
Lifeloc Technologies (OTC PINK:LCTC) reported Q2 2024 financial results with net revenue of $2.387 million, a 5% increase from Q2 2023. However, the company posted a net loss of $(298) thousand, or $(0.12) per diluted share, compared to a net income of $55 thousand in Q2 2023. Gross margin declined to 41.6% from 45.7% year-over-year. R&D investment increased by 67% to $662 thousand, primarily for SpinDx development.
The company highlighted progress in its L-series devices, including the launch of LX9 units with smartphone pairing. Lifeloc is focusing on developing the SpinDx technology platform for rapid drug detection, with beta testing planned for later in 2024 and commercial launch projected for 2025. To support development, Lifeloc secured a $750,000 line of credit and raised $798,000 through a private placement of shares.
Lifeloc Technologies, Inc. (OTC PINK:LCTC), a leader in breath alcohol testing devices, has appointed Adam Kashenberg to its Board of Directors, effective July 23, 2024. Kashenberg, president and CEO of Colorado Biolabs, Inc., brings expertise in sales, social media marketing, finance, and management. He replaces Bob Greenlee, who resigned after serving since 1989.
The company also completed a private placement at $3.80 per share, raising $798,000 from EDCO Partners, LLLP, now owning 77.5% of LCTC's common stock. Additionally, LCTC secured a $750,000 line of credit with Citywide Banks on July 19, 2024.
These funds will support LCTC's ongoing R&D efforts, particularly the development of SpinDx, a saliva testing system for delta-9-THC. Beta testing is expected to begin this year, with a commercial launch targeted for 2025.
FAQ
What is the current stock price of Lifeloc Technologies (LCTC)?
What is the market cap of Lifeloc Technologies (LCTC)?
